By Clinical Research News Staff 

September 9, 2024 | uMotif has acquired site platform provider ClinOne. The acquisition is the logical next step in a successful two-year strategic partnership between the companies to leverage a single, integrated solution for electronic clinical outcomes assessments (eCOA) and electronic informed consent (eConsent) technology. Financial details were not released.  

Two years ago, uMotif and ClinOne announced a partnership to provide integrated eCOA and eConsent technology. uMotif’s eCOA/electronic patient reported outcomes (ePRO) platform guides patients through the trial, ensuring uMotif customers capture the large amounts of data necessary to maximize the success of the trial. ClinOne connects, informs, and empowers sites with a single, integrated platform to improve consent management, increase site productivity, enhance trial awareness and the patient and caregiver experience.  

 “There are natural synergies between uMotif and ClinOne, and together, in addition to the most modern eCOA/ePRO solution on the market, we now offer our customers best-in-class consent management along with several additional tools to alleviate the site and patient burden,” said uMotif CEO Steve Rosenberg in a press release.  

 In the same statement, ClinOne CEO Andrea Valente commented, “We’re excited to integrate our solutions including eConsent, site productivity and trial awareness for HCPs into uMotif’s platform. Together we offer a breadth of capabilities to customers, sites and participants focused on quality, speed and an effective, purposeful experience.” Valente joins uMotif’s senior leadership team as Chief Operating Officer, Site Operations. 

The entire ClinOne team will be joining UMotif, a company spokesperson said.  While uMotif is based in London, the company already had a significant presence in the US. ClinOne is based in Needham, Mass.